Ziltivekimab Fails to Reduce Cardiovascular Events in ASCVD, CKD Patients

• Ziltivekimab, a monoclonal antibody, did not reduce cardiovascular events in patients with atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD).
• The ZEUS trial, conducted by Novo Nordisk, showed that the drug effectively lowered inflammatory biomarkers.
• Despite the drug's failure to limit serious heart events, cardiologists remain interested in anti-inflammatory treatments.
• The trial involved patients with severe illness, and the results were reported in July.
• The study highlights the ongoing challenge of managing inflammation in cardiovascular and metabolic diseases.